- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT04930731
Risk Factors and Characteristics of COVID 19 Infection in Patients With Haematological Diseases
- assessment of risk factor of covid 19 in haematological patients
- assessment of characteristics of covid 19 in haematological patients
Studieöversikt
Status
Betingelser
Detaljerad beskrivning
An ongoing outbreak of pneumonia associated with a novel coronavirus, severe acute respiratory syndrome (SARS) coronavirus 2, was reported in Wuhan, Hubei Province, China, in December 2019 .
In the following weeks, infections spread across China and other countries around the world .
The Chinese public health, clinical, and scientific communities took action to allow for timely recognition of the new virus and shared the viral gene sequence to the world .
On January 30, 2020, the World Health Organization (WHO) declared the outbreak a Public Health Emergency of International Concern
. On February 12, 2020, the WHO named the disease caused by the novel coronavirus "coronavirus disease 2019" (COVID-19) .
A group of international experts, with a range of specializations, have worked with Chinese counterparts to try to contain the outbreak .
Preliminary reports suggest that patients with an underlying malignancy have inferior outcomes.
While haematology patients are thought to be at increased risk of developing severe complications both due to immune dysfunction from their underlying haematological disorder and immunosuppressive therapies used for treatment, delays in treatment of the underling malignancy may compromise patient safety and survival. Data from other cohorts worldwide suggest mortality from COVID-19 is higher in haematology patients compared to the general population, with reported mortality rates between 39% and 50% in other British haematology patient cohorts.
In particular, a recent UK case series reported significantly higher case fatality rates in haematology patients receiving immunosuppressive or cytotoxic therapy within three months of COVID-19 diagnosis, raising concerns about the delivery of systemic anti-cancer therapy (SACT) during the pandemic.
There is an ongoing need to share collective experience regarding the clinical course of COVID-19 in patients with haematological disorders, particularly regarding implications for SACT delivery, in order to enable patients to receive treatment in a timely and safe manner during the pandemic.
Studietyp
Inskrivning (Förväntat)
Kontakter och platser
Studiekontakt
- Namn: Aya Nemr, Master
- Telefonnummer: 0201097069179
- E-post: Ayah.nemr@yahoo.com
Studera Kontakt Backup
- Namn: Essam E Mohamed
- Telefonnummer: 0201001971906
- E-post: essamabdelmohsen@aun.edu.eg
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Beskrivning
Inclusion Criteria:
- patients with haematological diseases who suspected or confirmed to COVID 19 infection..
- patients with age more than 18 years old
Exclusion Criteria:
- patients under the age of 18.
- Patients who refuse to contribute in this study.
Studieplan
Hur är studien utformad?
Designdetaljer
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Risk Factors and Characteristics of COVID 19 infection in Patients with Haematological Diseases
Tidsram: From September 2021 to June 2022
|
To identify risk factors and characteristics of COVID 19 in patients with haematological diseases
|
From September 2021 to June 2022
|
Samarbetspartners och utredare
Sponsor
Utredare
- Studiestol: Safaa A Ahmed, safaakhaled2003@gmail.com
Publikationer och användbara länkar
Allmänna publikationer
- Blimark C, Holmberg E, Mellqvist UH, Landgren O, Bjorkholm M, Hultcrantz M, Kjellander C, Turesson I, Kristinsson SY. Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica. 2015 Jan;100(1):107-13. doi: 10.3324/haematol.2014.107714. Epub 2014 Oct 24.
- Hilal T, Gea-Banacloche JC, Leis JF. Chronic lymphocytic leukemia and infection risk in the era of targeted therapies: Linking mechanisms with infections. Blood Rev. 2018 Sep;32(5):387-399. doi: 10.1016/j.blre.2018.03.004. Epub 2018 Mar 16.
- Chemaly RF, Ghosh S, Bodey GP, Rohatgi N, Safdar A, Keating MJ, Champlin RE, Aguilera EA, Tarrand JJ, Raad II. Respiratory viral infections in adults with hematologic malignancies and human stem cell transplantation recipients: a retrospective study at a major cancer center. Medicine (Baltimore). 2006 Sep;85(5):278-287. doi: 10.1097/01.md.0000232560.22098.4e.
- Pinana JL, Gomez MD, Montoro J, Lorenzo I, Perez A, Gimenez E, Gonzalez-Barbera EM, Carretero C, Guerreiro M, Salavert M, Sanz G, Hernandez-Boluda JC, Borras R, Sanz J, Solano C, Navarro D. Incidence, risk factors, and outcome of pulmonary invasive fungal disease after respiratory virus infection in allogeneic hematopoietic stem cell transplantation recipients. Transpl Infect Dis. 2019 Oct;21(5):e13158. doi: 10.1111/tid.13158. Epub 2019 Sep 3.
- Whimbey E, Englund JA, Couch RB. Community respiratory virus infections in immunocompromised patients with cancer. Am J Med. 1997 Mar 17;102(3A):10-8; discussion 25-6. doi: 10.1016/s0002-9343(97)80004-6.
Studieavstämningsdatum
Studera stora datum
Studiestart (Förväntat)
Primärt slutförande (Förväntat)
Avslutad studie (Förväntat)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- COVID 19 &haematological pts
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Covid19
-
Anavasi DiagnosticsHar inte rekryterat ännu
-
Ain Shams UniversityRekrytering
-
Israel Institute for Biological Research (IIBR)Avslutad
-
Colgate PalmoliveAvslutad
-
Christian von BuchwaldAvslutad
-
Luye Pharma Group Ltd.Shandong Boan Biotechnology Co., LtdAktiv, inte rekryterande
-
University of ZurichLabor Speiz; Swiss Armed Forces; Universitätsspital ZürichAnmälan via inbjudan
-
Alexandria UniversityAvslutad
-
Henry Ford Health SystemAvslutad